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Abstract
Background: Osteonecrosis of the jaw (ONJ) is a destructive bone process in patients undergoing bisphosphonate 
therapy and it is modulated by local and systemic factors. The purpose of this article is to determine the prevalence 
of ONJ in patients who have undergone intravenous bisphosphonate therapy, and relate the risk factors described 
to establish a protocol to reduce the risk of developing ONJ.
Material and Methods: We performed a retrospective study on 194 patients treated with IV bisphosponates, ana-
lyzing clinical and pathological variables.
Results: The prevalence of ONJ was 12.9 %. The most remarkable complication was pain, which was reported 
by 80% of patients. The average age of the patients undergoing bisphosphonate therapy was 68.91 years. Most of 
non-diabetic patients did not develop ONJ (92.3%) (p=0.048). During bisphosphonate therapy, 3.1% of patients 
underwent extractions in the same percentage in the maxilla and in the mandible; all of which, except for one 
patient, developed ONJ (p<0.001). In regards to the periodontal state, 94.3% of patients without periodontal 
problems did not develop ONJ (p=0.001). Almost 50% of the necrosis were located unifocally on the mandible 
(p<0.001). The number of affected patients and the aggressiveness of the disease increased significantly three 
years after starting treatment (p<0.001).
Conclusions: Etiology still is a controversial issue and we should focus on known risk factors, such as the devel-
opment of surgical procedures in patients undergoing bisphosphonate therapy, especially in patients who have 
already started their treatment, a group in which ONJ prevalence increases. Moreover, a bad periodontal state in 
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these patients is also an important risk factor, and the control of diabetes reduces it. Due to the above, all patients 
should be diagnosed and educated in oral hygiene prior to treatment, performing periodical maintenance, to detect 
possible traumatisms and periodontal infection as soon as possible.
Key words: Osteonecrosis of the jaws, intravenous bisphosphonate therapy.
Introduction
The term osteonecrosis of the jaw (ONJ) was used for 
the first time in 2003 in a series of cases with 36 bone 
lesions of the mandible or maxilla in patients undergo-
ing treatment with pamidronate or zolendronate.  But it 
wasn’t until 2007 that a definition and standardization 
of the process was established by the American Asso-
ciation of Oral and Maxillofacial Surgeons (AAOMS). 
The Association describes it as a destructive bone proc-
ess in patients undergoing bisphosphonate therapy who 
show bone exposure of over 8 weeks of evolution with-
out former radiotherapy treatment (1,2).
The pathophysiology of bisphosphonate-related os-
teonecrosis is still under debate in international litera-
ture. Different theories have been described and an ex-
tensive list of mechanisms has been proposed. The two 
most studied hypotheses are the suppression of bone 
remodeling and angiogenesis (3). Although many stud-
ies and revisions mention the suppression of bone re-
modeling when referring to bisphosphonate-related os-
teonecrosis, there are currently changes in this hypoth-
esis regarding three aspects. Firstly, osteonecrosis cases 
that are unrelated to the use of bisphosphonates have 
been described, in which other anti-remodeling agents 
have been used; secondly, bisphosphonate-related ONJ 
only occurs in the jaw and not in long bones or verte-
brae; thirdly, IV administration of bisphosphonates in-
creases the risk of osteonecrosis (4)
The risk factors that can contribute to the appearance 
of ONJ derive from the administration of bisphospho-
nates, systemic factors and local factors (5,6). The most 
relevant systemic factor is the presence of a malignant 
process, which is usually breast cancer, multiple my-
eloma or prostate cancer. Other influencing factors are 
diabetes, osteoporosis (in oncology patients) and medi-
cation related to steroids, immunosuppressive and an-
tiangiogenic drugs (5). 
Lastly, local factors are also related to the appearance of 
ONJ, such as oral hygiene and overall periodontal state. 
In most cases of bone necrosis, it appears after dental 
extractions, implant placement or lesions in the mucosa 
(7). The literature links dental extractions at the begin-
ning of ONJ as one of the most common factors in bone 
necrosis in patients undergoing bisphosphonate therapy 
(approximately 86%) (8).
The purpose of this article is to determine the preva-
lence of ONJ in patients who have undergone intrave-
nous bisphosphonate therapy, and relate the risk factors 
described to establish a protocol to reduce the risk of 
developing ONJ.
Material and Methods 
We performed a retrospective study on 194 patients, 
of which 139 (71.6%) were men and 55 (28.4%) were 
women, with an average age of 68.91, a standard devia-
tion of 11.69 and a range between 42 and 93 years. All 
of the patients visited the Master of Oral Medicine, Oral 
Surgery and Implantology of the Faculty of Medicine 
and Dentistry of Santiago de Compostela. The patients 
were derived from the Oncology Unit of the Comple-
joHospitalarioUniversitario of Santiago de Compostela 
(CHUS), for a dental examination prior to IV bisphos-
phonate therapy. All the patients who were submitted 
to IV  bisphosphonates over a period of 7 years (2006-
2013) were included in this study. This study has been 
approved by the Regional Ethics Committee Investiga-
tion of Galicia (2014/304) and all patients have received 
the consent informed.
All patients were treated with zoledronic acid. The main 
exclusion criteria was a history of treatment with ra-
diotherapy. We performed a complete medical history, 
dental and mucosa examination. As part of the protocol, 
we collected data on the patients regarding treatment, 
dental status and evolution. 
We analyzed the oral status of the patient at the time by 
performing a complete odontograph, assessing the peri-
odontal state, the use of removable prosthesis and the 
presence of torus or dental and bone plaques through 
additional tests, mainly orthopantomography.
The variables we collected included: hypertension, dia-
betes, treatment with cortisone and chemotherapy, pres-
ence or not of osteonecrosis, tooth extractions or other 
procedures before, during or after starting bisphospho-
nate therapy, presence of infection or teeth with unfa-
vorable prognosis, general periodontal state and the use 
of removable prosthesis.The patients with established 
osteonecrosis, we classified by degree of affectation, 
following the guidelines of Bagán et al. (9)
Statistical analysis
The collected data was analyzed with the SPSS statisti-
cal system, version 20.0 for Windows. The discontinu-
ous quantitative or discreet variables were analyzed 
through descriptive statistics, expressing the results in 
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mean, deviation and standard. The frequency tables and 
percentages were used for qualitative variables.
For the study of the association of variables we em-
ployed the Chi Square test, the T-Student test or the 
Anova Factor test, depending on the application condi-
tions. Values in which p ≤0.05 were considered statisti-
cally significant.
Results
Clinical and pathological characteristics of the sample 
and association analysis, are represented in table 1. Of 
the 25 patients (12.9%) who suffered ONJ, 8% had de-
gree 0, 24% degree I, 72% degree II and 8% degree III. 
Hardly any differences were appreciated between gen-
ders, except for the fact that the 2 degree III patients 
were women. We can see on figure 1, some examples of 
the different degrees of ONJ.
The complications appearing in patients undergoing 
bisphosphonate therapy were only observed in the 
patients that developed ONJ; except for one patient who 
had a temporary paresthesia of the mental region of the 
4th quadrant. The most remarkable complication was 
pain, which was reported by 80% of patients, followed 
by bone spicules (24%), abscesses (24%) and, in a lower 
degree, oroantral communication (4%) and extraoral 
fistula (4%). 
The average age of the patients undergoing bisphospho-
nate therapy was 68.91 years (range 25 to 101 years), 
which is very similar to the age of ONJ patients (68.97 
years), standard deviation 11.96, and a range between 42 
and 93 years. There were no statistically significant dif-
ferences (F =0.032, p=0.858). The gender of the patients 
did not show any statistical significant differences. Of 
the total study population of patients undergoing IV 
bisphosphonate therapy, 14 men (7.2%) and 11 women 
(5.7%) developed ONJ.  
The reason for IV bisphosphonate therapy was pros-
tate cancer in men (55.2%) and breast cancer in women 
(22.2%) followed by myeloma (9.3%) and lung cancer 
(7.7%), showing no differences between genders. All the 
patients were treated with zoledronic acid (Zometa®) at 
a 4mg dose and mostly in a monthly interval, except for 
one patient who received it quarterly.
In regards to systemic risk factors, most patients 
Table 1. Clinical and pathological characteristics of the sample and association anal-
ysis.
Characteristics
Total
patients with 
ONJ (%) 
Total patients 
without
ONJ (%) 
p
Gender 
     Men 
     Women 
14 (7.2) 
11 (5.7) 
125 (64.4) 
44 (22.7) 
0.063 
Systemic Risk Factor
Cancer 
     Prostate 
     Breast 
     Myeloma 
     Lung 
     Bladder 
     Colon 
     Kidney 
Diabetes 
Polymedicated 
HTA
Cortisone
QTP
12 (6.2) 
9 (4.6) 
4 (2) 
0 (0) 
0 (0) 
0 (0) 
0 (0) 
18 (9.3) 
168 (86.6) 
94 (48.5) 
42 (21.6) 
65 (33.5) 
11 (5.7) 
95 (49) 
34 (17.5) 
11 (5.7) 
18 (9.3) 
2 (1) 
5 (2.6) 
3 (1.5) 
176 (90.7) 
26 (13.4) 
100 (51.5) 
152 (78.4) 
129 (66.5) 
54 (27.8) 
0.214 
0.048 
0.139 
0.704 
0.234 
0.462 
Local Risk Factor
Extraction before 
Extraction during 
Extraction after 
Prosthesis
periodontal state 
8 (4.1) 
5 (2.6) 
4 (2) 
5 (2.6) 
19 (9.8) 
86 (44.3) 
1 (0.5%) 
7 (3.6) 
33 (17) 
70 (36) 
0.078 
<0.001 
0.017 
0.936 
0.001 
Toxic factors
Tobacco
Alcohol
2 (1) 
3 (1.5) 
13 (6.7) 
19 (9.8) 
0.998 
Location
Unifocal mandible 
Unifocal maxilla 
Multifocal mandible 
Maxilla and mandible 
13 (6.7) 
5 (2.6) 
3 (1.5) 
4 (2) 
-
-
-
-
< 0.001 
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(86.6%) who developed ONJ were polymedicated, re-
gardless of the consumption of drugs. The percentage of 
patients with hypertension (48.5%) as those treated with 
chemotherapy drugs (33.5%) and cortisone (21.6%) did 
not show any statistically significant differences. How-
ever, most of non-diabetic patients did not develop ONJ 
(92.3%) (X2=3.319, p=0.048).
In regards to dental extractions, 57.2% of the patients 
undergoing bisphosphonate therapy required dental ex-
tractions. 49% of the patients underwent tooth extrac-
tions before treatment, 13.4% of the upper jaw, 14.9% in 
the mandible and 20.6% in both jaws. During bisphos-
phonate therapy, 3.1% of patients underwent extractions 
in the same percentage in the maxilla and in the mandi-
ble; all of which, except for one patient, developed ONJ 
(X2=27.371,  p<0.001). Once bisphosphonate therapy 
had ended, tooth extractions were performed in 5.7% of 
patients, the remaining 88.5% that did not undergo tooth 
extractions did not develop ONJ (X2=5.725, p=0.017). 
We must highlight that 17 of 25 patients that developed 
ONJ did not undergo tooth extractions, although the dif-
ferences are not statistically significant.
As for local risk factors, of 38 patients with removable 
prosthesis, most of them (86.85%) did not suffer 
from ONJ and there were no statistically significant 
differences; while, in regards to the periodontal state 
(pocketsof >5mm and class II and III mobilities), 94.3% 
of patients without periodontal problems did not develop 
ONJ (X2= 10,488, p=0.001). Furthermore, most of the 
degree II ONJ patients (82.3%) and all of the degree III 
patients did have related periodontal problems.
As for related toxic factors, of the patients treated with 
bisphosphonates 7.7% were smokers, 11.3% had drink-
ing habits and 75.8% combined both factors. 76% of 
ONJ patients were not smokers nor drinkers, although 
there were no statistically significant differences.
The most affected areas by osteonecrosis were the 
lower jaw, followed by the upper jaw, and in a lower 
percentage (16%) both jaws. Almost 50% of the necrosis 
were located unifocally on the mandible, compared 
with the unifocal necrosis of the maxilla, which only 
accounted for 20% (X2=187,319, p<0.001).
In regards to the period lapsing from the beginning of the 
bisphosphonate therapy to the appearance of the lesions, 
exposed bone areas started appearing after one year. 
The number of affected patients and the aggressiveness 
of the disease increased significantly three years after 
starting treatment. 24% of patients suffered from bone 
exposure during the first year of treatment, 32% at 2-3 
years and 44% from 3 years onwards (X2=184,870, 
p<0.001).
Discussion
IV bisphosphonates are commonly used drugs for the 
treatment of patients with bone metastasis to avoid 
pathological fractures and reduce pain. In regards to the 
Fig. 1. Different degrees of ONJ.A) Degree I. B and C) Degree II. D) Degree III.
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type of bisphosphonate, it is important to distinguish 
the type, if it is nitrogenated or not, and the dose, dura-
tion and frequency of the treatment (cumulative doses) 
(5). The most relevant adverse effect described is os-
teonecrosis of the jaw, with a very variable prevalence 
according to the literature. It ranges between 0.7-12% 
(5,10,11), depending on the reviewed author, a similar 
figure as the one we obtained in our study (12.9%). Most 
ONJ processes are related to patients with prolonged 
treatments with nitrogenated IV bisphosphonates (5,6); 
furthermore, in regards to age and gender, we have ob-
served a greater predisposition in advanced ages and 
women, since malignant diseases and osteoporosis ap-
pearing at the same time as breast cancer are more fre-
quent in this type of patients (6).
All our patients received zoledronate (Zometa®), the 
bisphosphonate most frequently related to the appear-
ance of ONJ, surely because it is the most powerful and 
extensively used third generation bisphosphonate (12-
14). Bisphosphonates are mainly indicated for oncol-
ogy patients; in our case the most prevalent cancer was 
prostate cancer in men (52.2%), breast cancer in women 
(30.4%) followed by multiple myeloma (17.4%), which 
showed no differences between genders. Our data dif-
fers from the reviewed literature (15-17) since the oncol-
ogist deriving most patients to our service is specialized 
in prostate cancer.
In regards to the doses, few studies include the exact 
doses of the patients, as well as the periods between dos-
es. In our case, 91.3% of the patients received monthly 
doses of zoledronate, compared to 8.7% that received 
the doses quarterly. However, the literature concludes 
that higher doses of the drug increases the risk of de-
veloping ONJ (18,19). In regards to the period lapsing 
from the appearance of ONJ, once the bisphosphonate 
therapy has started, 24% of patients suffered from bone 
exposure during the first year of treatment, 32% at 2-3 
years, and 44% from 3 years onwards. According to the 
study published by Bamias, the risk of suffering from 
ONJ in patients with IV bisphosphonate therapy in-
creases from 39 months onwards, which coincides with 
the data collected in our study. 
Other risk factors are also included, such as treatment 
with cortisone, obesity, smoking, diabetes or treatment 
with chemotherapy (13); in our study we did not find 
any statistically significant differences regarding these 
variables.
Tooth extractions were described as a precursory fac-
tor in 86% of the cases in which osteonecrosis appeared 
in patients treated with bisphosphonate therapy (10,20). 
Dental extractions before and after bisphosphonate 
therapy did not show statistical significance. However, 
5 out of 6 patients who underwent extractions during 
the treatment with bisphosphonates developed ONJ.
We performed a conservative treatment with analgesics 
and antibiotics in the case of suppuration, in addition 
to a curettage and regularization of the areas with bone 
spicules. In those cases showing small areas of boneex-
posure (stage I) we proposed the use of a soft laser to 
vaporize the necrotic bone to reach the bleeding healthy 
bone. This minimally invasive technique allows us to 
create microperformations on the base of the bone and 
thus stimulate new vascularization. It also provides 
additional advantages such as its bactericide and bios-
timulation effect, while showing a better post-surgical 
recovery. We thus try to heal initial stages by trying to 
achieve a complete closure of the exposed bone (21,22).
In the most advanced cases (degree II), we conducted a 
microbiota study to best establish the antibiotic treat-
ment, although the period of treatment is not currently 
standardized (23,24). In the cases of degree III, surgi-
cal treatment was performed with bone resection and, 
in some cases, reconstruction of the area with a micro-
vascularized flap. In all of the cases, we insisted on cor-
rect oral hygiene and the use of antiseptic mouthwash 
(clorhexidine at 0.12%). Our entire protocol is in agree-
ment with the proposals of other authors of the reviewed 
literature (23,25).
Despite the treatment protocol proposed by several au-
thors, most of them agree that the most important factor 
is prevention to avoid the appearance of osteonecrosis 
of the jaw (26). Several publications show that preven-
tion reduces the risk of ONJ in patients undergoing IV 
bisphosphonate therapy (7,14,27). For this prevention, it 
is essential to conduct an extensive oral, dental and ra-
diographical assessment to detect bone or dental pathol-
ogies and treat them early on. Prevention by means of 
prior extraction of teeth with bad prognosis seems to be 
the appropriate measure. Of 94 patients in whom we de-
veloped this measure, 86 (91.5%) did not develop ONJ.
Conclusions
Etiology still is a controversial issue in regards to the 
appearance of ONJ and we should focus on known 
risk factors, such as the development of surgical pro-
cedures in patients undergoing bisphosphonate therapy, 
especially in patients who have already started their 
treatment, a group in which ONJ prevalence increases. 
Moreover, a bad periodontal state in these patients is 
also an important risk factor in the development of ONJ, 
and the control of diabetes reduces it. Due to the above, 
all patients should be diagnosed and educated in oral 
hygiene prior to treatment, performing periodical main-
tenance, paying special attention to the lower jaw, to de-
tect possible traumatisms and periodontal infection as 
soon as possible, which could eventually compromise 
healing and induce osteonecrosis later on.
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